This study on hydroxychloroquine had been described as “the largest known ‘wild’ therapeutic trial” in a column co-signed by doctors.
By Martin Pereira for Le Point
Published on
Subscriber-only audio playback
INational Medicines Safety Agency (ANSM) will take legal action. After a column asserting that the trials conducted by Didier Raoult on hydroxychloroquine were the “largest known “wild” therapeutic trial”, the ANSM informed, “after analysis”, with several media, “that this study can qualify as category 1 RIPH”. “This means that this study should have received a favorable opinion from a Committee for the Protection of Persons (CPP) and authorization from the ANSM to be implemented”.
The ANSM “is preparing to take legal action” therefore, continuing to overwhelm the former boss of the IHU, in Marseille. The latter announced, Friday evening, to have withdrawn the study in question: “All the authors (including me) of the pre-print which is so scary by showing that we could treat, decided, in solidarity with Professor Lagier threatened by management, to withdraw the pre-print so as not to suggest betrayal on his part and to protect the youngest, ”he wrote in a tweet.
We are the good guys!
All the authors (including me) of the preprint which is so scary by showing that we could treat, have decided, in solidarity with Professor Lagier threatened by the management, to withdraw the preprint so as not to suggest a betrayal of his leaves and for…— Didier Raoult (@raoult_didier) June 2, 2023
Preserve the IHU
“I think that the reputation of the Institut hospitalo-universitaire Méditerranée Infection (IHU) in Marseille is seriously enough in question today for this paper to be withdrawn in order to preserve the IHU”, explained to Agence France -Press the director of the AP-HM, François Crémieux. The president of Aix-Marseille University, Éric Berton, also estimated in an interview with AFP that this pre-print “does not serve the reputation” of the IHU, which needs to regain ” serenity “. He fears that this will delay the authorization of the Medicines Agency so that the IHU can resume clinical trials, which are currently suspended.
READ ALSOCovid: Raoult’s treatment, as effective as a “magic kiss” Dr. Marie Cachera, data analyst who dissected the study, was worried, in our columns: “Everything is dirty in this story. The figures presented in the study appendix show mortality rates of more than 40% in certain groups! Didier Raoult is stubborn, relentless and has continued to deliver dangerous molecules for certain types of patients for more than a year so as not to admit that he was wrong…”
Health Newsletter
List of hospitals and clinics, special files, tips and tricks… Every Tuesday, find our selection of articles from our Health section.
The editorial staff of Le Point advises you